Analysts Say Novartis To Emerge $1 Billion Richer With New Ranbaxy Ban
This article was originally published in PharmAsia News
Novartis and its Diovan (valsartan) blood-pressure drug could get another year on the market without a competitive challenge as a result of U.S. FDA action adding a third Ranbaxy Laboratories plant to its ban list.
You may also be interested in...
Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.
Apple and Johnson & Johnson are recruiting patients into Heartline, a 150,000-patient "virtual" randomized study to evaluate how the Apple watch can improve patient outcomes by reducing risk of stroke and detect atrial fibrillation early. See what Heartline's co-chair Michael Gibson of Harvard University said about it here.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.